Effectiveness of Transdiagnostic Cognitive Behaviour Therapy for Anxiety and Depression in Adults : A Systematic Review and Meta-analysis by Andersen, Phil et al.
Behavioural and Cognitive Psychotherapy, 2016, 44, 673–690
First published online 15 June 2016 doi:10.1017/S1352465816000229
Effectiveness of Transdiagnostic Cognitive Behaviour Therapy
for Anxiety and Depression in Adults: A Systematic Review
and Meta-analysis
Philip Andersen, Paul Toner and Martin Bland
University of York, UK
Dean McMillan
University of York, and Hull York Medical School, UK
Background: Transdiagnostic Cognitive Behaviour Therapy (CBT) seeks to identify core
cognitive-behavioural processes hypothesized to be important across a range of disorders and
to develop a treatment that targets these. This contrasts with standard CBT approaches that
are disorder-specific. Proponents of transdiagnostic CBT suggest that it may offer advantages
over disorder-specific CBT, but little is known about the effectiveness of this approach.
Aims: The review aimed to summarize trial-based clinical and cost-effectiveness data on
transdiagnostic CBT for anxiety and depression. Method: A systematic review of electronic
databases, including peer-reviewed and grey literature sources, was conducted (n = 1167
unique citations). Results: Eight trials were eligible for inclusion in the review. There was
evidence of an effect for transdiagnostic CBT when compared to a control condition. There
were no differences between transdiagnostic CBT and active treatments in two studies. We
found no evidence of cost-effectiveness data. Conclusions: Quality assessment of the primary
studies indicated a number of methodological concerns that may serve to inflate the observed
effects of transdiagnostic approaches. Although there are positive signs of the value of
transdiagnostic CBT, there is as yet insufficient evidence to recommend its use in place of
disorder-specific CBT.
Keywords: Transdiagnostic, cognitive behaviour therapy, systematic review, meta-analysis,
methodological quality, evidence-base
Introduction
Depression and anxiety are highly prevalent (Kessler, Chiu, Demler, Merikangas and Walters,
2005; McManus, Meltzer, Brugha, Bebbington and Jenkins, 2009), have substantial impacts
on quality of life and functioning for the individual (Haslam, Atkinson, Brown and Haslam,
2005; Paul and Moser, 2009) and are associated with substantial economic costs (Das-Munshi
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et al., 2008; Health and Safety Executive, 2012). Cognitive behaviour therapy (CBT) is an
effective treatment for a range of depressive (Butler, Chapman, Forman and Beck, 2006;
Hofmann, Asnaani, Vonk, Sawyer and Fang, 2012) and anxiety conditions (Olatunji, Cisler
and Deacon, 2010; Otte, 2011), but the vast majority of evidence for the effectiveness of this
approach is based on highly differentiated treatment protocols for specific diagnoses (NICE,
2011). An alternative approach, termed transdiagnostic CBT (tCBT), aims to identify a small
number of cognitive and behavioural processes that are common across a range of depressive
and anxiety conditions. These core processes are then used to develop a single treatment that
can be applied across a range of presentations.
Proponents of tCBT have put forward a number of potential advantages to this approach.
These include the possibility of offering more effective, efficient treatment of co-morbid
presentations (Borkovec, Abel and Newman, 1995), something that is common in depression
and anxiety presentations (Kessler et al., 2005). Furthermore, tCBT may reduce the training
needs of therapists (Schmidt et al., 2012). Since tCBT by definition should be effective for a
variety of different presentations, formation of ideally sized groups for group-delivered CBT
should be simplified (Norton and Philipp, 2008).
There are potential disadvantages to tCBT, not as widely discussed in the literature. Clinical
effectiveness may be diluted compared to diagnosis-specific treatments, because treatments
are designed to treat a wide variety of disorders (Craske et al., 2007). It is unclear whether
tCBT treatment is as acceptable to clients as disorder-specific CBT. When delivered in groups
with a mixture of presentations, it may be difficult for clients to empathize with and learn
as much from each other compared to groups in which clients have similar presentations
(McEvoy, Nathan and Norton, 2009).
Three previous reviews have examined the effectiveness of tCBT. The first, Norton and
Philipp (2008), was limited to anxiety studies. Of the nine studies reviewed, two were
randomized controlled trials (RCTs) (Erickson, Janeck and Tallman, 2007; Schmidt et al.,
2012) and one used a quasi-randomized design (Norton and Hope, 2005); the remainder
used uncontrolled designs. The review calculated a large overall within-group effect size of
transdiagnostic anxiety treatments (d = 1.29, 95% CI 0.66 to 1.93), compared to a small
within-group effect size for control conditions (d = 0.14, 95% CI −0.21 to 0.49). The authors
concluded that tCBT had considerable clinical utility, the preliminary data supporting the
efficacy of the interventions.
The second review, McEvoy et al. (2009), included 10 studies, with one RCT (Erickson
et al., 2007). The same quasi-randomized study was included, cited as two separate studies
(Norton, Hayes and Hope, 2004; Norton and Hope, 2005). The remainder were uncontrolled
studies. No meta-analysis of results was performed but a narrative synthesis concluded that
tCBT protocols were highly promising, although additional research was required.
The third review, Reinholt and Krogh (2014), included five RCTs (Erickson, Janeck and
Tallman, 2007; Farchione et al., 2012; Norton and Barrera, 2012; Roy-Byrne et al., 2010; and
Schmidt et al., 2012), the quasi-randomized Norton and Hope (2005) and six uncontrolled
studies. They reported a moderate combined effect size for all studies (SMD = -0.681, 95%
CI -0.903 to -0.458) favouring tCBT. The authors were more cautious in their conclusions
than the previous reviewers.
Although the reviews were broadly positive about the effectiveness of tCBT approaches,
caution is needed before accepting these conclusions. The reviews identified only a small
number of RCTs; the majority of studies were based on uncontrolled designs. The RCTs
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all compared tCBT to non-active control conditions, with the exception of Norton and
Barrera (2012). There were a number of methodological limitations of the reviews when
evaluated against standard guidelines for the conduct of systematic reviews (Moher, Liberati,
Tetzlaff, Altman and The PRISMA Group, 2009). There was limited description of search
strategies, and two reviews were limited to peer-reviewed publications, which may lead to
an overestimate of effects because of publication bias (Dwan et al., 2008; Song, Eastwood,
Gilbody, Duley and Sutton, 2000). There was limited evaluation of the methodological quality
of included studies. Two reviews were conducted by researchers involved in tCBT protocol
development. There is evidence that researcher allegiance can lead to inflated effect estimates
in RCTs of psychological treatments (Luborsky et al., 1999). The case for tCBT would be
strengthened by an additional independent review of the current evidence base.
Method
We adhered to the Centre for Reviews and Dissemination (2009) guidelines in the conduct of
the review and PRISMA guidelines (Moher et al., 2009) in the reporting of the review.
Search strategy
The following databases were searched to cover peer-review and grey literature sources:
PsycINFO, Medline, Embase, Cochrane Library, ASSIA, Web of Knowledge, OAIster, Open
Grey, Trip Database and ZETOC. Additional searches were conducted in NHS EED, HTA
Database, CEA Registry and RePEc health economic databases to identify relevant cost-
effectiveness data. Databases were searched from inception to June 2013, with no publication
status or language restrictions imposed.
Reference lists of included studies were examined, reverse-citation searches of included
studies were conducted and websites of researchers and study groups in the field of tCBT
were accessed to identify additional studies.
Search terms
Search terms, including free text and thesauri terms, were developed for PsycINFO and
adapted for other databases (Appendix A). Terms covered two broad constructs, CBT
and transdiagnostic treatment, combined using the Boolean AND. Search terms for CBT
were adapted, with permission, from a systematic review of low-intensity psychological
interventions (Rodgers et al., 2012). Search terms designed to capture the “transdiagnostic”
construct were derived from searches of books, studies and articles uncovered during scoping
searches. Thesauri available within the Ovid SP database were used to further inform search
terms related to CBT.
Study inclusion and exclusion criteria
A priori inclusion and exclusion criteria were developed around standard criteria.
Participants. Adults (aged 16 years or over). Participants at baseline met diagnostic
criteria for an anxiety or depressive disorder established by gold standard structured clinical
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interviews or scored above a clinical cut-off point on a standardized severity measure. To
ensure treatment was transdiagnostic, participants within studies must not have had uniform
diagnoses.
Intervention. The intervention had to be described as tCBT (or use related terms such as
Unified Protocol, mixed-diagnosis CBT, broad-spectrum CBT)
Comparator. Any comparison condition, including control or other active treatments.
Outcomes. Depression, anxiety or generic psychological wellbeing measured as a severity
score or a dichotomous outcome (e.g. depressed, not depressed) and health economic data.
Study design. Randomized controlled trials. Quasi-randomized and uncontrolled trials
were excluded.
Selection of studies
Two reviewers (PA, PT) used a pre-piloted eligibility form to assess studies. Disagreements
were resolved through consensus and, where necessary, discussion with a third reviewer
(DMcM). Titles and abstracts were first examined, and full papers obtained for studies passing
this initial sift. Full papers were then re-examined using the eligibility form to determine final
inclusion.
Data extraction
Data were extracted to a pre-piloted data extraction form by the primary reviewer (PA) and
checked by the secondary reviewer (PT). Extracted data included study name, year and type of
publication, authors, study location and setting, design, study sample characteristics, inclusion
and exclusion criteria, description of interventions and controls, follow-up length, outcomes
reported and data necessary to calculate effect sizes (e.g. means, standard deviations, sample
size).
Quality assessment
Methodological quality and sources of bias were assessed using the Cochrane risk of bias
assessment tool (Higgins et al., 2011) and an additional quality tool specifically tailored to
assess the quality of psychological RCTs (Yates, Morley, Eccleston and Williams, 2005).
Data synthesis
Standardized mean differences (SMD) with 95 percent confidence intervals using Hedges’s
adjusted g (Hedges, 1981) were calculated for anxiety, depression and general psychological
wellbeing severity measures.
Pre-planned comparisons. Results were grouped first by intervention type (individual or
group), second by comparator (control condition or active treatment) and finally by outcome
measure (anxiety, depression, general psychological wellbeing). If two or more studies were
similar in terms of the intervention, comparator and outcome type, a meta-analysis was
Effectiveness of transdiagnostic CBT 677
Additional records 
identified through 
other sources 
(n = 7) 
Records after duplicates removed 
(n = 1167) 
Records identified 
through database 
searching 
(n = 2306) 
Records screened 
(n = 1167) 
Records excluded 
(n = 1133) 
Full-text articles 
assessed for eligibility 
(n = 34) 
Full-text articles excluded 
(n = 26) 
 
Reasons for exclusion: 
Not true randomization 
(n = 11) 
Diagnostic criteria not met 
(n = 6) 
Not transdiagnostic CBT 
(n = 9) 
Studies included in 
qualitative synthesis 
(n = 8) 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n = 4) 
In
cl
ud
ed
 
El
ig
ib
ili
ty
 
Sc
re
en
in
g 
Id
en
tif
ic
at
io
n 
Figure 1. Search results and study selection flowchart
conducted. Heterogeneity was assessed using the I2 statistic, with values over 50% taken to
indicate substantial heterogeneity. Analyses were conducted in Review Manager 5 (Cochrane
Collaboration, 2012).
Results
Electronic database searches identified 2306 citations. Seven additional unique records were
identified through other sources. After removing duplicates, 1167 unique citations remained.
Screening titles and abstracts excluded 1133 citations, leaving 34 full-text articles to be
assessed. Of these, eight were judged eligible for inclusion in the review. Four studies were
meta-analysed (see Figure 1).
Of 34 full-text articles assessed, 26 were excluded for the following reasons: 11 studies did
not use randomization or used quasi-random methods of assigning participants to treatment;
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nine studies were excluded for not using recognizable tCBT treatment protocols; participants
in six studies did not meet diagnostic inclusion criteria (Appendix B).
Description of included studies
Table 1 summarizes the descriptive characteristics of the eight studies that met inclusion
criteria for the review (Erickson et al., 2007; Farchione et al., 2012; Johnston, Titov, Andrews,
Spence and Dear, 2011; Norton, 2012; Norton and Barrera, 2012; Schmidt et al., 2012; Titov,
Andrews, Johnston, Robinson and Spence, 2010; Titov et al., 2011).
Table 2 summarizes the principal diagnosis of the total sample. Social phobia (32.3%),
panic disorder (25.2%) and generalized anxiety disorder (29%) comprised the overwhelming
majority of diagnoses. Depression was the principal diagnosis in only 5.2% of the entire
sample.
Quality assessment of included studies
Table 3 summarizes the quality assessment of included studies using the Cochrane risk of bias
tool. All studies were deemed at high risk of bias for blinding of participants and personnel,
because this is typically inevitable in a trial of a psychological intervention. All studies
were judged at high risk of bias in “other sources of bias” because of potential for research
allegiance effects (treatment developers were the researchers evaluating their effectiveness).
Unclear random sequence generation prompted an unknown risk of bias for this criterion in
four studies (Erickson et al., 2007; Farchione et al., 2012; Norton, 2012; Norton and Barrera,
2012). Erickson et al. (2007) had an unknown risk of bias because of unclear information
concerning blinding of assessors. This study was also assessed to be at high risk of bias due to
selective reporting; two further were rated as having an unknown risk of bias on this quality
item (Norton, 2012; Norton and Barrera, 2012).
Assessment of treatment quality within included studies
The Yates assessment tool (Yates et al., 2005) was used to assess quality of treatment
administered in source studies. Items assessing description of treatment content and setting,
description of treatment duration and manualization of treatment protocols were rated as
present in all source studies. One study did not assess clinician adherence to the manual
(Farchione et al., 2012). One study provided no information concerning therapist training
(Erickson et al., 2007). Evidence of a lack of client engagement was identified in two studies
(Norton, 2012; Norton and Barrera, 2012) (Table 4).
Clinical effectiveness
Clinical effectiveness results are grouped by type of comparator and mode of treatment
delivery. Results are reported separately for each of the three main classes of primary outcome.
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Table 1. Characteristics of included studies
Study Setting and sample Intervention/s Comparator Treatment focus/outcomes
Erickson et al.
(2007)
Setting: Teaching hospitals,
University training clinic,
Canada
Age (years): (Mean ± SD)
Intervention: 40.7 ± 11.8
Comparator: 41.0 ± 11.1
Overall: 40.9 ± 11.4∗
Percent female: 63.8
Ethnicity: Not reported
Transdiagnostic CBT
11 X 120 minutes weekly
groups
Senior doctoral-level
psychologist with senior
graduate student
N = 73 (47 at post-treatment)
Waitlist / delayed treatment
N = 79 (41 at post-treatment)
Note: Waitlist group began
treatment 1 week after CBT
groups completed treatment
Treatment focus: Anxiety
Diagnosis: SCID
Anxiety severity: BAI
Depression severity: N/A
Generic measure: N/A
Measurement points:
Baseline, post-treatment,
6-months post-treatment
Farchione et al.
(2012)
Setting: University study
clinic, USA
Age (years): (Mean ± SD)
Intervention: 29.38 ± 9.86
Comparator: 30.64 ± 9.15
Overall: 29.75 ± 9.66∗
Percent female: 59.5
Ethnicity: 94.6% Caucasian
Transdiagnostic CBT –
Unified Protocol (UP)
18 X 60 minutes individual
sessions
Doctoral students, 2–4 years
experience; licensed
doctoral-level psychologist,
7 years experience
N = 26 (22 at post-treatment)
Waitlist / delayed treatment
N = 11 (10 at post-treatment)
Note: Waitlist group began
treatment 16 weeks after
start of trial
Treatment focus: Anxiety
Diagnosis: ADIS-IV
Anxiety severity: HARS, BAI
Depression severity: HRSD,
BDI-II
Generic measure: N/A
Measurement points:
Baseline, post-treatment,
6-months post-treatment
Johnston et al.
(2011)
Setting: Internet, Australia
Age (years): (Mean ± SD)
CL Group: 43.74 ± 13.36
CO Group: 38.63 ± 11.56
Comparator: 42.36 ± 13.20
Overall: 41.62 ± 12.83
Percent female: 58.8
Ethnicity: Not reported
1. Clinician assisted (CL)
transdiagnostic iCBT
(Anxiety Program)
8 units over 10 weeks
Clinical psychologist
N = 47 (42 at post-treatment)
2.Coach assisted (CO)
transdiagnostic iCBT
(Anxiety Program)
8 units over 10 weeks
Registered psychologist
N = 46 (39 at post-treatment)
Waitlist / delayed treatment
N = 46 (41 at post-treatment)
Note: Waitlist group began
treatment immediately after
iCBT groups completed
treatment
Treatment focus: Anxiety
Diagnosis: MINI
Anxiety severity: GAD-7
Depression severity: PHQ-9
Generic measure: DASS-21
Measurement points:
Baseline, post-treatment,
3-months post-treatment
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Table 1. Conitnued
Study Setting and sample Intervention/s Comparator Treatment focus/outcomes
Norton (2012) Setting: University anxiety
clinic, USA
Age (years): (Mean ± SD)
Overall: 32.98 ± 10.73
Percent female: 62.1
Ethnicity: 58.6% Caucasian
21.8% Hispanic/Latino
9.2% African American
4.6% Asian American
5.7% other or mixed
Transdiagnostic CBT
12 x 120 minutes weekly
groups
Doctoral-level graduate
students with experienced
senior graduate
co-therapists
N = 65 (37 at post-treatment)
Relaxation
12 x 120 mins weekly groups
Doctoral-level graduate
students with experienced
senior graduate
co-therapists
N = 22 (7 at post-treatment)
Treatment focus: Anxiety
Diagnosis: ADIS-IV
Anxiety severity: BAI
Depression severity: N/A
Generic measure: CGI-S
Measurement points:
Baseline, mid-treatment,
post-treatment
Norton and
Barrera
(2012)
Setting: University anxiety
clinic, USA
Age (years): (Mean ± SD)
Overall: 31.46 ± 8.93
Percent female: 50.0
Ethnicity: 54.3% Caucasian
23.9% Hispanic/Latino
10.9% African American
6.5% Asian American
4.3% Other or mixed
Transdiagnostic CBT
12 x 120 minutes weekly
groups
Doctoral-level graduate
students with experienced
senior graduate
co-therapists
N = 23 (16 at post-treatment)
(57 total randomized, 12
declined treatment –
allocation not stated)
Diagnosis-specific group CBT
12 x 120 mins weekly groups
Doctoral-level graduate
students with experienced
senior graduate
co-therapists
N = 23 (12 at post-treatment)
(See note in ‘Intervention/s’
column)
Treatment focus: Anxiety
Diagnosis: ADIS-IV
Anxiety severity: STAI
Depression severity: BDI-II
Generic measure: CGI-S
Measurement points:
Baseline, mid-treatment,
post-treatment
Schmidt et al.
(2012)
Setting: University outpatient
clinic, USA
Age (years): (Mean ± SD)
Intervention: 37.5 ± 11.3
Comparator: 34.6 ± 9.9
Overall: 36.3 ± 10.7∗
Percent female: 71.9
Ethnicity: 83% Caucasian
10% African American
7% other
Transdiagnostic CBT – False
Safety Behavior
Elimination Therapy
(F-SET)
10 x 120 minutes weekly
groups
Master’s-level therapists (1 to
2 years clinical experience),
experienced Ph.D.
postdoctoral fellow
N = 57 (53 at post-treatment)
Waitlist / delayed treatment
N = 39 (39 at post-treatment)
Note: Waitlist group began
treatment immediately after
CBT groups completed
treatment
Treatment focus: Anxiety
Diagnosis: SCID
Anxiety severity: SPRAS
Depression severity: BDI-II
Generic measure: CGI-S
Measurement points:
Baseline, post-treatment,
6-months post-treatment
(F-SET group only)
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Table 1. Conitnued
Study Setting and sample Intervention/s Comparator Treatment focus/outcomes
Titov et al.
(2010)
Setting: Internet, Australia
Age (years): (Mean ± SD)
Intervention: 38.6 ± 12.0
Comparator: 40.5 ± 14.1
Overall: 39.5 ± 13.0
Percent female: 67.9
Ethnicity: Not reported
Transdiagnostic iCBT
(Anxiety Program)
6 units over 8 weeks
Clinical psychologist via
weekly telephone calls or
instant messaging
N = 42 (36 at post-treatment)
Waitlist / delayed treatment
N = 44 (36 at post-treatment)
Note: Waitlist group began
treatment immediately after
iCBT group completed
treatment
Treatment focus: Anxiety
Diagnosis: MINI
Anxiety severity: GAD-7
Depression severity: PHQ-9
Generic measure: DASS-21
Measurement points:
Baseline, post-treatment,
3-months post-treatment
(treatment group only)
Titov et al.
(2011)
Setting: Internet, Australia
Age (years): (Mean ± SD)
Intervention: 44.8 ± 14.9
Comparator: 42.9 ± 14.5
Overall: 43.9 ± 14.6
Percent female: 73.0
Ethnicity: Not reported
Transdiagnostic iCBT
(Wellbeing Program)
8 units over 10 weeks
Clinical psychologist via
weekly telephone calls or
instant messaging
N = 39 (34 at post-treatment)
Waitlist / delayed treatment
N = 38 (35 at post-treatment)
Note: Waitlist group began
treatment immediately after
iCBT group completed
treatment
Treatment focus: Anxiety or
depression
Diagnosis: MINI
Anxiety severity: GAD-7
Depression severity: PHQ-9
Generic measure: DASS-21
Measurement points:
Baseline, post-treatment,
3-months post-treatment
(treatment group only)
Notes: ∗ Calculated using pooled variance; ADIS-IV = Anxiety Disorders Interview Schedule for the DSM-IV; BAI = Beck Anxiety Inventory; BDI-II
= Beck Depression Inventory (1996 revision); CBT = cognitive behavior therapy; CGI-S = Clinical Global Impressions - Severity scale; DASS-21 =
Depression Anxiety Stress Scales - short-form version; F-SET = False Safety Behavior Elimination Therapy; GAD-7 = Generalized Anxiety Disorder
7-item scale; iCBT = internet CBT; MINI = Mini International Neuropsychiatric Interview Version 5.0.0; N = number of participants; N/A = not
available; PHQ-9 = Patient Health Questionnaire - 9; SCID = Structured Clinical Interview for DSM-IV Axis I Disorders; SD = standard deviation;
HARS = Hamilton Anxiety Rating Scale; HRSD = Hamilton Rating Scale for Depression; SPRAS = Sheehan Patient-Rated Anxiety Scale; STAI =
State-Trait Anxiety Inventory
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Table 2. Principal diagnosis of included participants
Principal diagnosis: N %
Social phobia 226 30.9
Panic disorder, with or without agoraphobia 177 24.2
Generalized anxiety disorder 203 27.7
Posttraumatic stress disorder 17 2.3
Obsessive-compulsive disorder 25 3.4
Specific phobia 8 1.1
Anxiety disorder not otherwise specified 4 0.5
Social phobia and anxiety NOS 1 0.1
Generalized anxiety disorder and social phobia 1 0.1
Obsessive-compulsive disorder and panic disorder 1 0.1
Major depressive disorder 38 5.2
Not reported 31 4.2
Total 732 100
Table 3. Cochrane risk of bias assessment tool summary
Random
sequence
generation
Allocation
conceal-
ment
Blinding of
participants
and
personnel
Blinding of
outcome
assessment
Incomplete
outcome
data
Selective
reporting
Other
bias
Erickson 2007 ? ? − ? − − −
Farchione 2012 ? ? − + + + −
Johnston 2011 + + − + + + −
Norton 2012a ? ? − + − ? −
Norton 2012b ? ? − + − ? −
Schmidt 2012 + + − − + + −
Titov 2010 + + − + + + −
Titov 2011 + + − + + + −
Notes: + low risk of bias; − high risk of bias; ? unknown risk of bias
Table 4. Yates et al. (2005) treatment quality assessment tool
Treatment
content /
setting
Treatment
duration Manualization
Adherence
to manual
Therapist
training
Client en-
gagement
Total
score
Erickson 2007 2 1 2 1 1 1 8
Farchione 2012 2 1 2 0 2 1 8
Johnston 2011 2 1 2 1 2 1 9
Norton 2012a 2 1 2 1 2 0 8
Norton 2012b 2 1 2 1 2 0 8
Schmidt 2012 2 1 2 1 2 1 9
Titov 2010 2 1 2 1 2 1 9
Titov 2011 2 1 2 1 2 1 9
Notes: Maximum total score is 9; higher scores denote lower bias
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Study or Subgroup
Farchione 2012
Johnston 2011
Titov 2010
Titov 2011
Total (95% CI)
Heterogeneity: Tau² = 0.07; Chi² = 6.38, df = 3 (P = 0.09); I² = 53%
Test for overall effect: Z = 4.87 (P < 0.00001)
Mean
7.39
6.17
7.43
6.81
SD
5.37
4.38
4.7
5.05
Total
26
89
40
37
192
Mean
13.08
11.79
11.42
9.29
SD
4.22
4.6
5.55
4.6
Total
11
42
38
37
128
Weight
15.6%
30.4%
27.0%
26.9%
100.0%
IV, Random, 95% CI
-1.10 [-1.85, -0.35]
-1.26 [-1.65, -0.86]
-0.77 [-1.23, -0.31]
-0.51 [-0.97, -0.04]
-0.90 [-1.26, -0.54]
Transdiagnostic CBT Waitlist Std. Mean Difference Std. Mean Difference
IV, Random, 95% CI
-2 -1 0 1 2
Favors CBT Favors Waitlist
Figure 2. Individual transdiagnostic CBT vs. control conditions, anxiety measures
Study or Subgroup
Farchione 2012
Johnston 2011
Titov 2010
Titov 2011
Total (95% CI)
Heterogeneity: Tau² = 0.02; Chi² = 2.45, df = 2 (P = 0.29); I² = 19%
Test for overall effect: Z = 6.46 (P < 0.00001)
Mean
7.39
6.17
7.43
6.81
SD
5.37
4.38
4.7
5.05
Total
26
89
40
37
155
Mean
13.08
11.79
11.42
9.29
SD
4.22
4.6
5.55
4.6
Total
11
42
38
37
91
Weight
16.2%
46.5%
37.3%
0.0%
100.0%
IV, Random, 95% CI
-1.10 [-1.85, -0.35]
-1.26 [-1.65, -0.86]
-0.77 [-1.23, -0.31]
-0.51 [-0.97, -0.04]
-1.05 [-1.37, -0.73]
Transdiagnostic CBT Waitlist Std. Mean Difference Std. Mean Difference
IV, Random, 95% CI
-2 -1 0 1 2
Favors CBT Favors Waitlist
Figure 3. Individual transdiagnostic CBT vs. control conditions, anxiety measures, excluding Titov
et al. (2011)
Study or Subgroup
Farchione 2012
Johnston 2011
Titov 2010
Titov 2011
Total (95% CI)
Heterogeneity: Tau² = 0.10; Chi² = 6.10, df = 2 (P = 0.05); I² = 67%
Test for overall effect: Z = 3.79 (P = 0.0002)
Mean
7.39
6.17
7.43
6.81
SD
5.37
4.38
4.7
5.05
Total
26
89
40
37
166
Mean
13.08
11.79
11.42
9.29
SD
4.22
4.6
5.55
4.6
Total
11
42
38
37
117
Weight
0.0%
35.5%
32.3%
32.2%
100.0%
IV, Random, 95% CI
-1.10 [-1.85, -0.35]
-1.26 [-1.65, -0.86]
-0.77 [-1.23, -0.31]
-0.51 [-0.97, -0.04]
-0.86 [-1.30, -0.41]
Transdiagnostic CBT Waitlist Std. Mean Difference Std. Mean Difference
IV, Random, 95% CI
-2 -1 0 1 2
Favors CBT Favors Waitlist
Figure 4. Individual transdiagnostic CBT vs. control conditions, anxiety measures, excluding Farchione
et al. (2012)
Individual tCBT versus control conditions
Anxiety severity measures. Four studies provided posttreatment data from anxiety scales
for individual tCBT versus waitlist control conditions (Farchione et al., 2012; Johnston et al.,
2011; Titov et al., 2010, 2011) (see Figure 2). Farchione et al. (2012) used the Hamilton
Anxiety Rating Scale (M. Hamilton, 1959) while the remaining studies utilized GAD-7
(Spitzer, Kroenke, Williams and Löwe, 2006). The data were re-analysed excluding Titov
et al. (2011), a potential outlier (see Figure 3). To assess any difference between internet
versus face to face treatment we excluded the single face to face study, Farchione et al. (2012)
(see Figure 4).
Depression severity measures. The same four studies provided posttreatment data from
depression scales (Figure 5). Farchione et al. (2012) utilized the Hamilton Rating Scale for
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Study or Subgroup
Farchione 2012
Johnston 2011
Titov 2010
Titov 2011
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.67, df = 3 (P = 0.64); I² = 0%
Test for overall effect: Z = 5.40 (P < 0.00001)
Mean
5.49
6.88
8.28
8.13
SD
4.63
5.21
5.9
5.98
Total
26
89
40
37
192
Mean
7.85
11.29
11.47
11.32
SD
4.01
5.28
6.99
5.1
Total
11
42
38
37
128
Weight
10.6%
37.5%
26.8%
25.1%
100.0%
IV, Random, 95% CI
-0.52 [-1.23, 0.20]
-0.84 [-1.22, -0.46]
-0.49 [-0.94, -0.04]
-0.57 [-1.03, -0.10]
-0.64 [-0.88, -0.41]
Transdiagnostic CBT Waitlist Std. Mean Difference Std. Mean Difference
IV, Random, 95% CI
-2 -1 0 1 2
Favors CBT Favors Waitlist
Figure 5. Individual transdiagnostic CBT vs. control conditions, depression measures
Study or Subgroup
Farchione 2012
Johnston 2011
Titov 2010
Titov 2011
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.54, df = 2 (P = 0.46); I² = 0%
Test for overall effect: Z = 5.22 (P < 0.00001)
Mean
5.49
6.88
8.28
8.13
SD
4.63
5.21
5.9
5.98
Total
26
89
40
37
166
Mean
7.85
11.29
11.47
11.32
SD
4.01
5.28
6.99
5.1
Total
11
42
38
37
117
Weight
0.0%
41.9%
29.9%
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100.0%
IV, Random, 95% CI
-0.52 [-1.23, 0.20]
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Figure 6. Individual transdiagnostic CBT vs. control conditions, depression measures, excluding
Farchione et al. (2012)
Study or Subgroup
Johnston 2011
Titov 2010
Titov 2011
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.52, df = 2 (P = 0.47); I² = 0%
Test for overall effect: Z = 6.07 (P < 0.00001)
Mean
28.67
33.15
32.8
SD
21.71
22.69
22.9
Total
89
40
37
166
Mean
48.48
53.42
44.86
SD
20.41
28.78
20.87
Total
42
38
37
117
Weight
42.1%
29.2%
28.8%
100.0%
IV, Random, 95% CI
-0.92 [-1.31, -0.54]
-0.78 [-1.24, -0.32]
-0.54 [-1.01, -0.08]
-0.77 [-1.02, -0.52]
Transdiagnostic CBT Waitlist Std. Mean Difference Std. Mean Difference
IV, Random, 95% CI
-2 -1 0 1 2
Favors CBT Favors Waitlist
Figure 7. Individual transdiagnostic CBT vs. control conditions, generic measures
Depression (Hamilton, 1960) while the remaining studies used the PHQ-9 (Kroenke, Spitzer
and Williams, 2001). For comparison, Farchione et al. (2012) was again excluded (Figure 6).
Generic severity measures. Three studies provided posttreatment data from generic scales
for mental health (Johnston et al., 2011; Titov et al., 2010, 2011) (see Figure 7). Each used
the DASS-21 (Lovibond and Lovibond, 1995).
Group tCBT versus control conditions
Anxiety severity measures. Two studies provided posttreatment anxiety data for group
tCBT versus a control condition (Erickson et al., 2007; Schmidt et al., 2012). Erickson
et al. (2007) used the BAI (Beck and Steer, 1990) while Schmidt et al. (2012) used the
SPRAS (Sheehan, 1983). Results are not meta-analysed because of substantial heterogeneity
(I2=80%, p = 0.03). Individual effect sizes are summarized in Figure 8.
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Study or Subgroup
Erickson 2007
Schmidt 2012
Mean
17.5
34.35
SD
11.7
18.35
Total
47
53
Mean
18.6
50.78
SD
12.4
24.48
Total
41
39
IV, Random, 95% CI
-0.09 [-0.51, 0.33]
-0.77 [-1.20, -0.34]
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Figure 8. Group transdiagnostic CBT vs. control conditions, anxiety measures
Depression severity measures. Only Schmidt et al. (2012) provided posttreatment
depression-specific severity data, using the BDI-II (Beck, Steer and Brown, 1996). The SMD
was −0.38, favouring tCBT (95% CI −0.80 to 0.04).
Generic severity measures. Schmidt et al. (2012) alone provided posttreatment generic
mental health severity data. They used the CGI (Guy, 1976). The SMD was −0.99, favouring
tCBT (95% CI −1.43 to −0.55).
Individual tCBT versus other active treatments. No studies compared individual tCBT to
another active treatment.
Group tCBT versus other active treatments.
Anxiety severity measures. Two studies provided posttreatment data from anxiety scales
for group tCBT versus active treatment (Norton, 2012; Norton and Barrera, 2012). Norton
(2012) used the BAI while Norton and Barrera (2012) used the STAI (Spielberger, Gorsuch,
Lushene, Vagg and Jacobs, 1983). The studies were not meta-analysed because treatments,
relaxation and disorder-specific CBT, were not considered similar enough that combining
them would be meaningful. For Norton (2012) the SMD was −0.24 (95% CI −0.73 to 0.24),
a non-significant difference favouring group tCBT over relaxation. The SMD for Norton
and Barrera (2012) was 0.06 (95% CI −0.51 to 0.64), a non-significant difference favouring
diagnosis-specific group CBT over group tCBT.
Depression severity measures. Norton and Barrera (2012) provided posttreatment
depression-specific severity data using the BDI-II. The SMD was −0.25 (95% CI −0.83 to
0.33).
Generic severity measures. Both Norton (2012) and Norton and Barrera (2012) provided
posttreatment generic mental health severity using the severity scale of the CGI (CGI-S). The
SMD for Norton (2012) was −0.24 (95% CI −1.56 to 1.08). The SMD for Norton and Barrera
(2012) was −0.22 (95% CI −1.35 to 0.92).
Cost-effectiveness
There were no studies identified that examined the cost-effectiveness of tCBT.
Discussion
The aim of the review was to assess the effectiveness of tCBT as evaluated in RCTs for
depression and anxiety in adults. We identified eight studies, the majority of which were small
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(total N = 732). One RCT included in the Reinholt and Krogh (2014) review was excluded
because the intervention was a tailored CBT treatment rather than a single transdiagnostic
protocol (Roy-Byrne et al., 2010). Four studies were of individual tCBT versus control
conditions. These found evidence of significant effects in the moderate to large range for
the outcomes of anxiety, depression and measures of generic mental health symptomatology.
Two studies compared group tCBT with control conditions. Of the two studies, Schmidt et al.
(2012) found some evidence of the effectiveness of tCBT, with significant effects ranging
from small to large, though the effect reported for anxiety in Erickson et al. (2007) was non-
significant. Only two studies compared tCBT to other active treatments, both of which used
a group format of delivery. A meta-analysis was not conducted because of differences in the
active treatment conditions. There was no indication of significant differences between tCBT
and the other active treatment conditions. We found no data on the cost-effectiveness of tCBT
treatment.
Limitations
These results must be considered in the light of both the limitations of the current review
method and the primary studies themselves. Although we developed a systematic review
protocol at an early stage of the review, we did not publish this on a database such as
PROSPERO. Alternative definitions of transdiagnostic CBT, such as that offered by McEvoy
et al. (2009), may be preferable to the operational definition we used because of the greater
level of specificity offered.
Our review identified only eight RCTs involving tCBT. Although we made efforts to
search grey literature, it cannot be ruled out that unpublished trials were missed, especially if
descriptive terms used for treatments differed greatly from that found in scoping searches for
this review. We found too few studies to formally assess the possibility of publication bias.
Allocation concealment is considered a key methodological standard of RCTs because
there is evidence that absence of allocation concealment is associated with increased effect
sizes (Schulz and Grimes, 2002; Wood et al., 2008). Four studies had unclear risk of bias
for this item on the Cochrane risk of bias tool (Erickson et al., 2007; Farchione et al., 2012;
Norton, 2012; Norton and Barrera, 2012). It is possible that estimates of effectiveness are
overestimated in these studies. All studies were conducted by researchers who developed the
transdiagnostic treatment protocols, a risk for researcher allegiance effects (Munder, Brütsch,
Leonhart, Gerger and Barth, 2013). This may also be associated with inflated effect sizes.
Three studies were rated as either unclear or high risk of bias for selective reporting of
outcome data (Erickson et al., 2007; Norton, 2012; Norton and Barrera, 2012). This form of
bias typically inflates treatment effects, because results that are not positive may be less likely
to be reported. Of concern was the absence of clear statements regarding primary outcome
measures. This is a particular concern for the evaluation of transdiagnostic treatment, because
it may not be clear what the most relevant outcome measure should be.
In summary, there are a number of methodological limitations of the primary studies, each
of which may artificially increase observed effect sizes. This places an important caveat
around the generally positive findings. Additional caveats include the small number of trials
identified. Studies comparing tCBT to an active comparator were particularly scarce. The
review found no transdiagnostic treatment cost-effectiveness evidence.
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Research implications
The limitations of the primary studies suggest a number of implications for future research.
First, future RCTs should adhere to accepted methodological standards for RCTs to
minimize the possibility of bias. Adherence to the CONSORT statement in trial reporting
would substantially improve this situation (Schulz, Altman and Moher, 2010). Researchers
should publish trial protocols in which all proposed outcomes are stated and primary
outcomes identified a priori. There is as yet an absence of independent evaluation of
transdiagnostic treatments; trials to date have been conducted by researchers who developed
the transdiagnostic protocols and are therefore at risk of researcher allegiance effects. Future
research teams should consist of, in the words of Leykin and DeRubeis (2009), researchers
“who possess complementary areas of expertise, and correspondingly opposite allegiances.”
While a number of studies provided follow-up data beyond the end of treatment it was
not possible to calculate between-group effect sizes because, at the end of the treatment
phase, control condition participants were immediately offered treatment. There is substantial
evidence that disorder-specific CBT has an effect that continues beyond the end of treatment
(Hollon, Stewart and Strunk, 2006; Steinert, Hofmann, Kruse and Leichsenring, 2014). Future
trials should seek to use designs in which the ability of tCBT to reduce relapse relative to other
conditions is examined. Future studies comparing tCBT to disorder-specific treatments should
follow accepted standards for the design and analysis of non-inferiority RCTs (Fleming,
Odem-Davis, Rothmann and Shen, 2011; Piaggio et al., 2012).
There are surprisingly few RCTs of transdiagnostic approaches covering both depression
and anxiety presentations. There may be value in future studies examining the effectiveness
of treatments designed for both anxiety and depressive presentations, particularly given the
high degree of co-morbidity between these.
Future studies should incorporate concurrent economic evaluations, as this has not yet been
formally evaluated. There would be value in adding qualitative components into future trials
to establish the acceptability of tCBT interventions for both clinicians and clients.
Conclusions
The evidence base for tCBT as applied to anxiety and depression is at an early stage of
development. While there are encouraging signs that the approach may be effective, it is
important to consider the methodological limitations of the primary studies, many of which
may serve to artificially inflate the observed effect of the intervention. There is very limited
evidence on the comparative effectiveness of disorder-specific and transdiagnostic CBT
approaches and an absence of cost-effectiveness evidence. Despite the encouraging signs,
there is as yet insufficient evidence to recommend the use of tCBT in place of disorder-specific
CBT approaches.
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